Guardant Health AMEA
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
January 8, 2024 SINGAPORE — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC (“Hikma”), a multinational pharmaceutical company,
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
September 5, 2023 SINGAPORE — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Japanese Ministry of Health, Labour
Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan
July 5, 2023 TOKYO – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it has been informed it
Guardant Health Receives Regulatory Approval from Singapore’s Health Sciences Authority for Guardant360® CDx blood test for patients with advanced solid cancers
May 30, 2023 SINGAPORE — Guardant Health, Inc. (Nasdaq: GH) announced today that Singapore’s Health Sciences Authority (HSA) has granted regulatory approval of Guardant360® CDx,
Guardant Health and Adicon announce strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China
July 6, 2022 SINGAPORE — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Adicon Holdings Limited, a leading independent
Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture
June 13, 2022 SINGAPORE– Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it has purchased the remaining shares of
Guardant Health Receives Regulatory Approval for Guardant360® CDx in Japan
March 14, 2022 TOKYO — The Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Guardant360® CDx, a liquid
Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa
December 15, 2020 MUMBAI, India — 15 December 2020 — Guardant Health Asia, Middle East and Africa (AMEA) has won Frost &
First liquid biopsy to receive FDA Approval for comprehensive tumor mutation profiling across all solid cancers, Guardant Health’s Guardant360® CDx, advancing precision oncology in Asia, Middle East and Africa
August 7, 2020 SINGAPORE — The U.S. Food and Drug Administration (FDA) has approved Guardant Health’s liquid biopsy, Guardant360 CDx, for tumor
Guardant360® test results may provide prognostic information beyond the detection of actionable biomarkers for ALK-rearranged NSCLC patients
May 30, 2020 SINGAPORE — According to the data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on 29 May 2020, researchers